Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 4 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 08 Dec 2016

Icotinib improves progression-free survival (PFS) and objective response rate (ORR) vs whole-brain irradiation (WBI) plus chemotherapy in Chinese patients with non-small-cell lung cancer (NSCLC) and brain metastases, according to a phase III study presented recently at the 17th World Conference on Lung Cancer (WCLC).

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Triplet regimen of encorafenib, binimetinib and cetuximab extends survival in BRAF V600E-mutated mCRC

Dr Margaret Shi
14 Nov 2019

The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.

After a median follow-up of 7.8 months, patients randomized to receive triplet therapy had a significant improvement in OS compared with the control group of patients who received investigators’ choice of either cetuximab plus irinotecan or cetuximab plus FOLFIRI (folinic acid, 5-FU and irinotecan) (median, 9.0 months vs 5.4 months; hazard ratio [HR], 0.52; 95 percent confidence interval [CI], 0.39 to 0.70; p<0.01), with consistent results demonstrated in subgroup analyses. Median OS of patients who received doublet therapy with encorafenib plus cetuximab vs the control group was 8.4 months vs 5.4 months (HR, 0.60; 95 CI, 0.45 to 0.79; p<0.001). [N Engl J Med 2019;381:1632-1643]

ORR based on independent review was also significantly increased with the triplet regimen compared with the control regimen (26 percent vs 2 percent; p<0.001).

Likewise, PFS was improved in the triplet-therapy group compared with the doublet-therapy group and the control group (median, 4.3 months vs 4.2 months vs 1.5 months; HR, 0.38; 95 percent CI, 0.29 to 0.49) after a median follow-up of 5.4 months.

The BECAON CRC trial was a global, multicentre, randomized, open-label, phase III trial, in which 665 patients were randomized (1:1:1) to receive triplet therapy (n=224), doublet therapy (n=220), or investigators’ choice of a control regimen (n=221).

The median duration of exposure to trial treatment was 21 weeks, 19 weeks and 7 weeks in the triplet-therapy group, doublet-therapy group and the control group, respectively.

The BRAFV600E mutation occurs in approximately 10 percent of patients with mCRC. Initial standard chemotherapy for BRAFV600E-mutated CRC is known to be associated with poor outcomes. The triplet regimen evaluated in the trial was designed to provide maximum inhibition of the mitogen-activated protein kinase (MAPK) pathway. Previous studies have shown promising activity of encorafenib in combination with cetuximab compared with triplet regimens of an anti-EGFR agent with a BRAF inhibitor plus either a MEK inhibitor or irinotecan. [J Clin Oncol 2017; 35:Suppl:3505; Cancer Discov 2018;8:428-443; J Clin Oncol 2016;34:3544-3544]

Although the current trial was not powered to compare the triplet regimen with the doublet regimen directly, a benefit in OS was demonstrated with the triplet therapy compared with the doublet therapy (HR, 0.79; 95 percent CI, 0.59 to 1.06).

Adverse events (AEs) of grade 3 or above occurred at similar rates across all treatment groups (58 percent vs 50 percent vs 61 percent), with gastrointestinal-related and skin-related events being the most common AEs in the triplet-therapy group. The AE profiles of both combination regimens allowed the maintenance of a high dose intensity for the majority of patients, and were consistent with the known AE profile of each agent.

“Further follow-up is needed to better define the relative benefits of the triplet and doublet regimens,” added the authors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 4 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 08 Dec 2016

Icotinib improves progression-free survival (PFS) and objective response rate (ORR) vs whole-brain irradiation (WBI) plus chemotherapy in Chinese patients with non-small-cell lung cancer (NSCLC) and brain metastases, according to a phase III study presented recently at the 17th World Conference on Lung Cancer (WCLC).

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).